These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11317472)

  • 1. A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting.
    Schuitemaker GE; van der Pol GA; Aretz CP; Dinant GJ
    Eur J Clin Pharmacol; 2001 Mar; 56(12):857-63. PubMed ID: 11317472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency.
    Kirsten R; Heintz B; Nelson K; Sieberth HG; Oremek G; Hasford J; Speck U
    Eur J Clin Pharmacol; 1988; 34(2):133-7. PubMed ID: 3383985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnesium pyridoxal-5'-phosphate glutamate, "A vitamin B6 derivative", does not affect lipoprotein levels in patients with familial hypercholesterolaemia.
    Knipscheer HC; Kindt I; van den Ende A; Nurmohamed MT; Smalbraak H; Mulder WJ; Kastelein JJ
    Eur J Clin Pharmacol; 1997; 51(6):499-503. PubMed ID: 9112067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf.
    Al-Rasadi K; Al-Zakwani I; Al Mahmeed W; Arafah M; Al-Hinai AT; Shehab A; Al Tamimi O; Alawadhi M
    Curr Med Res Opin; 2014 Dec; 30(12):2429-35. PubMed ID: 25222765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of magnesium pyridoxal 5-phosphate glutamate in rabbits developing hypercholesterolemia.
    Panagiotopoulos T; Ketelsen UP; Schmidt A; Heuck CC
    Arzneimittelforschung; 1986 Aug; 36(8):1210-5. PubMed ID: 3778558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels: a double-blind placebo-controlled randomized clinical trial.
    Hajmohammadi Z; Heydari M; Nimrouzi M; Faridi P; Zibaeenezhad MJ; Omrani GR; Shams M
    J Integr Med; 2018 Jan; 16(1):45-50. PubMed ID: 29397092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
    J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
    Hartgens F; Rietjens G; Keizer HA; Kuipers H; Wolffenbuttel BH
    Br J Sports Med; 2004 Jun; 38(3):253-9. PubMed ID: 15155420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
    Insull W; Davidson MH; Demke DM; Dujovne CA; Eckert SM; Ginsberg D; Goldberg AC; Hodis HN; Hughes TA; Kane JP
    Atherosclerosis; 1995 Jan; 112(2):223-35. PubMed ID: 7772081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of magnesium pyridoxal 5-phosphate glutamate on vascular reactivity in experimental hypercholesterolemia.
    Khayyal MT; Khayyal MA; Sharaf HM; el-Sherbeeny M; Okpanyi SN; Schneider W
    Drugs Exp Clin Res; 1998; 24(1):29-40. PubMed ID: 9604146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
    Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.